NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
Clinical Trials
12 trialsNCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00565851 2025-12-30
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00176254 2023-05-16
Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer
University of Kentucky
Phase 2 Completed
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT02440425 2022-10-07
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00152477 2022-04-12
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
UCB Pharma
Phase 2 Completed
NCT03128008 2021-05-28
ADAPT
Duke University
Phase 2 Completed
NCT02920450 2019-10-04
UF-STO-LUNG-002
University of Florida
Phase 1/2 Terminated
NCT00570674 2017-11-13
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT00226590 2017-03-23
Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00737243 2016-08-17
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed